瑞典全国队列研究:RASi基础上加用利尿剂与钙通道阻滞剂对CKD进展及死亡的影响比较
该研究在瑞典肾脏登记库中模拟目标试验,纳入5875例中晚期CKD且已用RASi的患者,比较启动利尿剂(3165例)与CCB(2710例)的结局。中位随访6.3年,利尿剂组主要肾脏不良事件风险较低(加权HR 0.87,95%CI 0.77-0.97),而主要心血管事件与全因死亡无差异。观察性研究提示,在晚期CKD患者中,RASi基础上加用利尿剂而非CCB可能改善肾脏结局且不损害心脏保护。
要点
- 中位随访6.3年,利尿剂组主要肾脏不良事件风险低于CCB组(加权HR 0.87,95%CI 0.77-0.97)。
- 主要心血管事件(加权HR 1.14,95%CI 0.96-1.36)与全因死亡(加权HR 1.07,95%CI 0.94-1.23)两组无差异。
- 观察性研究提示,晚期CKD患者在RASi基础上加用利尿剂而非CCB可能改善肾脏结局。
核心结论
- 观察性研究提示,在晚期CKD患者中,RASi基础上加用利尿剂而非CCB可能改善肾脏结局,且不损害心脏保护。
研究设计与样本
- 在瑞典肾脏登记库2007-2022年数据中模拟目标试验,纳入肾病科转诊的中晚期CKD且已用RASi、启动利尿剂或CCB的患者。
- 共纳入5875例患者,中位年龄71岁,64%为男性,中位eGFR 26 ml/min/1.73m2;其中3165例启动利尿剂,2710例启动CCB。
- 采用倾向评分加权的原因别Cox回归比较结局。
主要发现
- 中位随访6.3年,发生2558例主要肾脏不良事件、1178例主要心血管事件和2299例死亡。
- 与CCB相比,利尿剂与较低的主要肾脏不良事件风险相关(加权HR 0.87,95%CI 0.77-0.97),各单一组分结果一致(肾脏替代治疗:HR 0.77,95%CI 0.66-0.88;eGFR较基线下降超过40%:HR 0.80,95%CI 0.71-0.91;eGFR低于15 ml/min/1.73m2:HR 0.84,95%CI 0.74-0.96)。
- 主要心血管事件(加权HR 1.14,95%CI 0.96-1.36)与全因死亡(加权HR 1.07,95%CI 0.94-1.23)在两种治疗间无差异。
- 在建模总药物暴露时间、各亚组及广泛敏感性分析中,结果一致。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
It is unknown whether initiating diuretics on top of renin-angiotensin system inhibitors (RASi) is superior to alternative antihypertensive agents such as calcium channel blockers (CCBs) in patients with chronic kidney disease (CKD). For this purpose, we emulated a target trial in the Swedish Renal Registry 2007-2022 that included nephrologist-referred patients with moderate-advanced CKD and treated with RASi, who initiated diuretics or CCB. Using propensity score-weighted cause-specific Cox regression, we compared risks of major adverse kidney events (MAKE; composite of kidney replacement therapy [KRT], experiencing over a 40% eGFR decline from baseline, or an eGFR under 15 ml/min per 1.73m2), major cardiovascular events (MACE; composite of cardiovascular death, myocardial infarction or stroke), and all-cause mortality. We identified 5875 patients (median age 71 years, 64% men, median eGFR 26 ml/min per 1.73m2), of whom 3165 started a diuretic and 2710 a CCB. After a median follow-up of 6.3 years, 2558 MAKE, 1178 MACE and 2299 deaths occurred. Compared to CCB, diuretic use was associated with a lower risk of MAKE (weighted hazard ratio 0.87 [95% confidence interval: 0.77-0.97]), consistent across single components (KRT: 0.77 [0.66-0.88], over 40% eGFR decline: 0.80 [0.71-0.91] and eGFR under 15ml/min/1.73m2: 0.84 [0.74-0.96]). The risks of MACE (1.14 [0.96-1.36]) and all-cause mortality (1.07 [0.94-1.23]) did not differ between therapies. Results were consistent when modeling the total time drug exposure, across sub-groups and a broad range of sensitivity analyses. Thus, our observational study suggests that in patients with advanced CKD, using a diuretic rather than a CCB on top of RASi may improve kidney outcomes without compromising cardioprotection.
引用
- Faucon AL, Fu EL, Stengel B, et al. A nationwide cohort study comparing the effectiveness of diuretics and calcium channel blockers on top of renin-angiotensin system inhibitors on chronic kidney disease progression and mortality. Kidney Int. 2023. PMID: 37330214. doi:10.1016/j.kint.2023.05.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。